Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Recruiting
NCT06997588Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Australia, Austria, Belgium, France +5 more
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active Not Recruiting
NCT05156281Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Brazil, Bulgaria, Canada +22 more
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic ImpairmentRecruiting
NCT07422610Phase 1Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Malignancies and Hepatic Impairment
France, Italy, Spain, United Kingdom
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompleted
NCT01742299Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
GIST and CML
United States, China, Finland, France, Hong Kong +6 more
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07489573Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
China
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.Recruiting
NCT06905288N/AUpdated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Ankylosing Spondylitis
South Korea
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM PredictorsTerminated
NCT05853458Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Polycythemia Vera
Germany
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRecruiting
NCT07340190Phase 1Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Malignancies
France, Italy, Spain
Secukinumab Open Label Roll-over Extension ProtocolRecruiting
NCT04638647Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Autoimmunity, Inflammation
United States, Brazil, Bulgaria, China, Colombia +15 more
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruiting
NCT07226986Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
United States, Australia, France, Germany, Italy +2 more
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompleted
NCT03106779Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
United States, Argentina, Australia, Brazil, Bulgaria +20 more
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruiting
NCT07665437Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
United States, Argentina, Australia, Canada
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive Not Recruiting
NCT03701334Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +15 more
A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy PatientsNot Yet Recruiting
NCT07767890N/AUpdated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
Spinal Muscular Atrophy
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Recruiting
NCT06858319Phase 3Updated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
Kidney Diseases · Kidney Diseases, Chronic · Urological Diseases · Glomerulonephritis
United States, Argentina, Australia, Canada, Malaysia +4 more
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.Recruiting
NCT07440290Phase 2, Phase 3Updated Aug 17, 2026
Sponsor: Cancer Research UK
Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type
United Kingdom
A 52-week Study of Remibrutinib in IgE-mediated Food AllergyNot Yet Recruiting
NCT07768371Phase 3Updated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
IgE-Mediated Food Allergy · Peanut Allergy · Cow Milk Allergy · Egg Allergy
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsActive Not Recruiting
NCT06857955Phase 2Updated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
Hypertension
United States, Japan, Singapore
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruiting
NCT07085767Phase 3Updated Aug 17, 2026
Sponsor: Olema Pharmaceuticals, Inc.
Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast Cancer · ER Positive Breast Cancer
United States, Australia, Austria, Belgium, Canada +18 more
Specified Drug-use Surveillance of Fabhalta CapsulesActive Not Recruiting
NCT06606314N/AUpdated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
Japan
A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesNot Yet Recruiting
NCT07767877N/AUpdated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
Vascular Anomalies
Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung CancerCompleted
NCT01167530Phase 1Updated Aug 17, 2026
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Non-small Cell Lung Cancer · Locally Advanced Disease
France
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical PracticeTerminated
NCT07036718N/AUpdated Aug 17, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
Russia
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With HypertensionCompleted
NCT06604897N/AUpdated Aug 14, 2026
Sponsor: Novartis Pharmaceuticals
Essential Hypertension
United States
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.Recruiting
NCT06236724Phase 2Updated Aug 14, 2026
Sponsor: M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
United States

Previous page Next page